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54 Poster Session IHCT co-morbidity index scores, disease status, donor source, and
acute and chronic GVHD, similar risks for developing hypothy-
roidism were observed between the two types of conditioning reg-
imens (relative risk for MA 1.6 [95% CI, 0.4–5.8] vs. RIC).
Female gender was the only factor predictive for hypothyroidism
(relative risk 4.5 [95% CI, 1.1–18.0] vs. males). In conclusion, hypo-
thyroidism is relatively infrequent in adult allogeneic HCT survi-
vors. At least in the first few years post-HCT, RIC is associated
with similar risks for hypothyroidism as MA conditioning.142
HIGH PREVALENCE OF IRON OVERLOAD IN ADULT SURVIVORS OF AL-
LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Majhail, N.S.1, DeFor, T.E.1, Kang, B.2, Paley, C.2, Lazarus, H.3,
Burns, L.J.1 1University of Minnesota, Minneapolis, MN; 2Novartis
Pharmaceuticals, East Hanover, NJ; 3Case Western Reserve University,
Cleveland, OH.
Iron overload is a well recognized complication of transfusion de-
pendent anemias. A large number of allogeneic hematopoietic cell
transplant (HCT) recipients receive red blood cell (RBC) transfu-
sions and pre-HCT serum ferritin has been reported to be an inde-
pendent predictor for early transplant related mortality. However,
the prevalence of iron overload in long-term allogeneic transplant
survivors is not known. We report a cross-sectional study of iron
overload in this population. Adult allogeneic HCT recipients
were eligible if they: (1) had survived for $12 months from their
transplant, (2) had no active infections, (3) had no active flare of
chronic graft-versus-host disease, and (4) had no contraindication
for magnetic resonance imaging (MRI) scan. Patients who con-
sented for participation were screened with serum ferritin (normal
range 10–300 ng/mL), and those with serum ferritin .1000 ng/
mL underwent R2 MRI of the liver to measure liver iron concentra-
tion (LIC, normal range 0.17–1.8 mg/g dry tissue) using the Ferri-
Scan technology, a highly sensitive and specific technique for
measuring hepatic iron content (St Pierre et al, Blood 2005, 105:
855). Iron overload was defined as LIC above the normal range
(.1.8 mg/g). Forty eight patients were enrolled and were a median
of 27 (range, 12–151) months from HCT. All were RBC transfusion
independent at the time of study enrollment. Median age was 49
(range, 24–69) years and 54% were males. The most common indi-
cations for HCT were acute leukemia (44%) and non-Hodgkin’s
lymphoma (31%). Eighteen patients had serum ferritin .1000
ng/mL (median 1516 [range, 1003–7311]); of these 17 had iron
overload on MRI (median LIC 7.5 (range, 2.8–28.3) mg/g), with
an overall prevalence rate of 35% (95% confidence intervals [CI],
22–51%). Clinically significant iron overload (LIC .5 mg/g) was
present in 11 patients (23% [95% CI, 12–37%]). LIC level on
MRI was only moderately correlated with serum ferritin level (r 5
0.49 [95% CI, 0.10–0.88]) and transferrin saturation level (r 5
0.55 [95% CI, 0.13–0.97]). In conclusion, iron overload is a frequent
late complication of allogeneic HCT. Serum ferritin is a good initial
screening test but it may not predict the level of hepatic iron content
and may not be useful by itself for identifying clinically significant
iron overload. More studies are needed to determine the natural his-
tory and treatment of iron overload in allogeneic HCT survivors.
Total Myeloablative/ Medianpatients
(N 5 48) mNon-
yeloablative URelated/
nrelated tRBC units
ransfusedMedian
ferritin Median LICFerritin
#1000
(N 5 30)
18/12 20/10 8 364 ng/mL Not done
per protocolFerritin
.1000
(N 5 18)
13/5 12/6 24 1516 ng/mL 7.5 mg/g**17/18 patients had iron overload (liver iron concentration .1.8
mg/g on liver R2 MRI).143
PRE-TRANSPLANT PULMONARY FUNCTION AND DAY 100 NON-RE-
LAPSE MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Basu, S.K.1, Liesveld, J.L.1, Trawick, D.R.2, Fernandez, D.3,
Nichols, D.1, Fisher, S.G.3 1University of Rochester, Rochester, NY;
2University of Rochester, Rochester, NY; 3University of Rochester,
Rochester, NY.
This study’s purpose was to evaluate the association between pul-
monary function, as measured by the diffusion capacity of the lung
for carbon monoxide (DLCO), before hematopoietic stem cell
transplantation (HSCT) and non-relapse mortality (NRM) at 100
days post-transplant. The rationale was that DLCO, as an early in-
dicator of lung disease or as a measure of pre-existing systemic en-
dothelial damage, might be a predictor of NRM.
Methods: This was a retrospective cohort study of all patients
undergoing their first HSCT at the University of Rochester be-
tween 1995 and 2004. NRM at 100 days (Day100NRM) was the pri-
mary outcome. DLCO, as percent predicted, corrected for
hemoglobin, was the main independent variable. The chi-square
test, Mantel-Haenszel test of trend, and analysis of variance were
used for categorical, ordinal, and continuous variables respectively
in bivariate analyses. Logistic regression was used for multivariate
analysis. Results: Data regarding DLCO, mortality, and patient
characteristics were available from 677 (95%) patients. By 100
days, 59 subjects died without having a relapse. Day100NRM was
8.5% (95% confidence interval: 6.4, 10.8%). Pulmonary complica-
tions (27%), graft-versus-host disease (15%), and multi-organ fail-
ure (14%) were the most frequent causes of Day100NRM. On
crude analysis, using DLCO in quartiles, there was a statistically
significant association (chi-square p 5 0.0179) and dose response
relationship (trend test p 5 0.0023) between DLCO and
Day100NRM. Of multiple variables analyzed, only race, smoking
status, diagnosis, body mass index, forced expiratory volume at
one second, forced vital capacity, serum alkaline phosphatase, and
serum albumin, had a statistically significant association with
DLCO and were included in multivariate testing. In the final mul-
tivariate model, low DLCO, low serum albumin, and type of cancer
diagnosis remained significantly associated with Day100NRM. The
odds ratio for DLCO was 1.442 (95% confidence interval: 1.103,
1.885), using DLCO in quartiles as an ordinal variable. Patients
in the lowest quartile of DLCO were almost three-times (odds ratio
5 2.99) as likely as patients in the highest quartile of DLCO to ex-
perience Day100NRM. Conclusions: There was a statistically sig-
nificant association and a dose-response relationship between pre-
transplant DLCO and Day100NRM. These results suggest that
the DLCO may be helpful at the time of the pre-transplant evalua-
tion in predicting risk of Day100NRM.144
FREQUENCY OF ABNORMAL FINDINGS DETECTED BY COMPREHENSIVE
EVALUATION AT ONE YEAR AFTER HEMATOPOIETIC CELL TRANSPLAN-
TATION
Lee, S.J.1, Seaborn, T.2, Massey, S.2, Mao, F.J.2, Luu, N.2,
Moravec, C.1, Carpenter, P.A.1, Martin, P.J.1, Flowers, M.E.D.1
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University
of Washington, Seattle, WA.
Medical records of 118 adults (88% of eligible patients alive with-
out relapse) who returned for evaluation at one year after allogeneic
hematopoietic cell transplantation (HCT) in 2005 were reviewed in
order to document the frequency of abnormal findings and to assess
the value of routine long-term follow-up (LTFU) assessments after
HCT. Most (n5 102, 86%) spent 2–3 days in Seattle for testing and
consultation, while 16 (14%) brought results of diagnostic testing
performed elsewhere. The cohort included 69 (58%) men and 49
women (42%), 47 (40%) who received reduced intensity condition-
ing, 62 (53%) with unrelated donors, 105 (89%) who received
growth-factor mobilized blood cells, and 18 (15%) who had second
transplants. Sixteen additional patients were alive at 1 year without
known recurrent malignancy who did not return for evaluation.
There were no statistically significant differences in the age, gender,
Poster Session I 55donor type, conditioning regimen, and frequency of second trans-
plants between patients who did or did not return for the 1 year eval-
uation. Among the 106 (90%) patients who had no prior evidence of
recurrent malignancy after HCT, 4 (4%) were diagnosed with re-
current malignancy during the LTFU visit. Among the 31 (26%)
patients had no prior diagnosis of chronic GVHD, 9 (29%) were di-
agnosed with chronic GVHD during the LTFU visit. The table
shows the overall prevalence of abnormal findings and the types
of clinical recommendations documented in letters to the referring
physician. Most patients were immunized during the LTFU visit.
Pre-immunization titers were protective against pneumococcus in
55% of patients, haemophilus influenza B in 21%, tetanus in 36%
and hepatitis B in 26%; 95% required additional doses of at least
one vaccine. Bone and lipid abnormalities and absence of protective
antibody titers to pneumococcus, haemophilus, tetanus and hepati-
tis B were not associated with current or previous history of chronic
GVHD, current use of steroids or calcineurin inhibitors or number
of immunosuppressive agents, suggesting that all patients should be
tested. We conclude that routine comprehensive LTFU evaluation
at one year after allogeneic HCT detects a high frequency of med-
ical problems requiring active intervention or adjustment of ther-
apy. While the ultimate effect on health outcomes is unknown,
our experience suggests that systematic evaluation at one year after
HCT is an important part of monitoring for late effects.
Prevalence of problems and frequencies of recommendations
Recommendations*Problem PrevalenceContinuation
of current
managementDose change
or new
medicationsActive chronic GVHD 64% 19% 79%Abnormal iron studies 71% 26% 15%Elevated fasting lipids 56% 21% 18%Abnormal thyroid tests 22% 52% 16%Osteopenia 1 osteoporosis 52% 1 6% 42% 44%*Among patients with problem.Impact of Insurance Coverage
Insurance
Approval,
Days
Time to
Transplant,
Days
N Median Mean Range Median Mean Range
Insurance
Coverage
24 41 53 0–155 106 119 13–346
Insurance
Limitations
9 93 130 22–275 218 240 109–497
*Restrictions 4 68 81 22–168 232 268 109–497
*No Coverage 5 174 169 90–275 218 219 128–371145
REDUCED INTENSITY CONDITIONING (RIC) IS ASSOCIATED WITH
SHORTER DURATION OF CHRONIC GVHD THAN MYELOABLATIVE CON-
DITIONING AND PROVIDES VERY GOOD QUALITY OF LIFE FOR LONG-
TERM SURVIVORS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Shimoni, A., Hardan, I., Shem-Tov, N., Rand, A., Ribakovsky, E.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-
Hashomer, Israel.
RIC has been increasingly used over the last decade in patients
(pts) not eligible for myeloablative conditioning (MC). RIC allows
consistent engraftment with reduced toxicity, yet the long-term ef-
fects, the duration of immunosuppressive therapy (IST) and quality
of life in long-term survivors are less defined. We compared out-
comes of 48 pts given RIC to 41 pts given MC from 1/2000 to 8/
2002. The median age was 49 (range, 20–65) and 37 (20–65) years
in the RIC and MC groups, respectively (p5 0.01). The MC group
included more pts with acute leukemia/MDS (68% vs 33%, p 5
0.001) while pts with myeloma were given only RIC (31% of the
RIC group, p\ 0.001). 48% of pts in the RIC and none in the
MC group had a prior autologous SCT (p\0.001). After a median
follow-up of 6.1 years (range, 5.1–7.6) 40 pts are alive, 20 after RIC
and 20 after MC with estimated survival of 42% (95 ci, 28–56) and
47% (95 ci, 31–63), respectively (p5NS). Long-term survival with
RIC was achieved across all diagnoses including 6 of 16 pts with
acute leukemia/MDS, 6 of 6 pts with CML, 3 of 11 pts with lym-
phoid malignancies and 5 of 15 pts with myeloma. The correspond-
ing rates in the MC group were 13 of 28, 3 of 4, 4 of 9, and 0 of 0,
respectively. Chronic GVHD occurred in 22 pts after RIC [cumu-
lative incidence 48%(35–65)] and in 26 pts after MC [66%(53–83),
(p 5 0.07)]. 12 pts with chronic GVHD after RIC were eventually
able to stop IST, 9 died on IST (relapse-5, non-relapse-4) and only1 of 20 long-term survivors was still on IST at last follow-up. The
median duration of IST was 17 months and the probability of stop-
ping IST after 5 years was 79%. In the MC group 10 pts with
chronic GVHD were able to stop IST, 8 died on IST (relapse-6,
non-relapse-2) and 8 of 20 long-term survivors were still on IST
at last follow-up. The median duration of IST was 41 months (p
5 0.05) and the probability of stopping IST after 5 years was
48% (p 5 0.001). Two women gave birth in the RIC group while
2 men in the MC group fathered children spontaneously. There
was one secondary malignancy in the MC group and 2 pts sustained
myocardial infarction (one fatal). One pt in the RIC group had re-
versible nephrotic syndrome. In summary long term survival is sim-
ilar after RIC and MC SCT, however IST is significantly shorter
after RIC. All 20 pts surviving more than 5 years after RIC sustained
excellent quality of life and only one still required IST. These obser-
vations require further confirmation in larger registry studies.146
IMPACT OF HEALTH INSURANCE ON TIME TO APPROVAL AND TIME TO
TRANSPLANT AMONG PATIENTS RECEIVING HEMATOPOIETIC STEM
CELL TRANSPLANTATION
McHenry, M., Hayes-Lattin, B., Maziarz, R.T. Oregon Health and Sci-
ence University, Portland, OR.
Access to hematopoietic stem cell transplantation (HSCT),
a therapy that can be curative for patients with various life-threaten-
ing disorders, is often limited by a patient’s health insurance cover-
age. It is difficult to quantitate the impact of health insurance on
referrals to a transplant center, and health insurance status may be
one of several reasons for not undergoing HSCT after an initial
consultation. However, we hypothesize that even among patients
who receive HSCT, insurance coverage influences the timing of
transplant. We retrospectively analyzed the time to obtaining insur-
ance approval and to proceeding to HSCT based on insurance sta-
tus for that type of procedure at the time of the initial consultation.
During the first quarter of 2006, 16 patients proceeded to autolo-
gous and 17 proceeded to allogeneic HSCT. Patients were catego-
rized as having an insurance plan that covered their transplant or
that had limitations. Limitations included either no coverage or in-
surance restrictions, such as initial denial requiring an appeal, no
coverage for HLA-typing or search, or a waiting period. More
than 25% of patients receiving either autologous or allogeneic
HSCT experienced limitations imposed by their health insurance
coverage. The median time to insurance approval (41 versus 93
days) and the median time to transplant (106 versus 218 days) was
more than twice as long for those with limitations imposed by their
insurance plan. Patients who initially had no transplant coverage
ultimately received their transplant earlier than those with other
restrictions, by either changing insurance plans or paying out-of-
pocket. A complete analysis of 2006 will be updated at the time of
presentation. This method of analysis undoubtedly underestimates
the true impact of insurance coverage. Patients who have delays may
experience disease relapse or other morbidity during that delay
which precludes proceeding to HSCT. Even among those patients
who were referred to our transplant center and received HSCT,
the covered transplant may not have followed the initial
